{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:54:02Z","timestamp":1790776442450,"version":"4.1.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH101874"],"award-info":[{"award-number":["MH101874"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH122379"],"award-info":[{"award-number":["MH122379"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH101874"],"award-info":[{"award-number":["MH101874"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH123748"],"award-info":[{"award-number":["MH123748"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH122379"],"award-info":[{"award-number":["MH122379"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH108901"],"award-info":[{"award-number":["MH108901"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH108901"],"award-info":[{"award-number":["MH108901"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013395","name":"WUSTL | Washington University School of Medicine in St. Louis | Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM151160-01"],"award-info":[{"award-number":["R35GM151160-01"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001455","name":"American Foundation for Suicide Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001455","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41380-025-03439-6","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T04:27:52Z","timestamp":1766982472000},"page":"3022-3032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rapid antidepressant potential of nitrous oxide: current state and major questions"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-5154","authenticated-orcid":false,"given":"Charles F.","family":"Zorumski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Cichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5596-1031","authenticated-orcid":false,"given":"Yukitoshi","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-4577","authenticated-orcid":false,"given":"Thomas","family":"Zeffiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0868-0664","authenticated-orcid":false,"given":"Steven","family":"Mennerick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8369-3858","authenticated-orcid":false,"given":"Peter","family":"Nagele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"3439_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41386-023-01632-1","volume":"49","author":"JN Johnston","year":"2024","unstructured":"Johnston JN, Kadriu B, Kraus C, Henter ID, Zarate CA Jr. Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacol. 2024;49:23\u201340.","journal-title":"Neuropsychopharmacol"},{"key":"3439_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamapsychiatry.2016.2586","volume":"74","author":"CR Conway","year":"2017","unstructured":"Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression. When enough is enough. JAMA Psychiatry. 2017;74:9\u201310.","journal-title":"JAMA Psychiatry"},{"key":"3439_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune M, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22:394\u2013412.","journal-title":"World Psychiatry"},{"key":"3439_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41386-023-01647-8","volume":"49","author":"AF Schatzberg","year":"2024","unstructured":"Schatzberg AF, Mathew SJ. The why, when, how, and so what of so-called rapidly acting antidepressants. Neuropsycopharmacol. 2024;49:189\u201396.","journal-title":"Neuropsycopharmacol"},{"key":"3439_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1176\/appi.ajp.20240515","volume":"182","author":"KN Fountoulakis","year":"2025","unstructured":"Fountoulakis KN, Saitis A, Schatzberg AF. Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis. Am J Psychiatry. 2025;182:259\u201375.","journal-title":"Am J Psychiatry"},{"key":"3439_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41386-023-01721-1","volume":"49","author":"R Patterson","year":"2024","unstructured":"Patterson R, Balan I, Morrow AL, Meltzer-Brody S. Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions. Neuropsychopharmacol. 2024;49:67\u201372.","journal-title":"Neuropsychopharmacol"},{"key":"3439_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41386-023-01656-7","volume":"49","author":"JM Mitchell","year":"2024","unstructured":"Mitchell JM, Anderson BT. Psychedelic therapies reconsidered: compounds, clinical indications and cautious optimism. Neuropsychopharmacol. 2024;49:96\u2013103.","journal-title":"Neuropsychopharmacol"},{"key":"3439_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/bs.apha.2020.04.002","volume":"89","author":"WC Drevets","year":"2020","unstructured":"Drevets WC, Bhattacharya A, Furey ML. The antidepressant efficacy of the muscarinic antagonist scopolamine: past findings and future directions. Adv Pharmacol. 2020;89:357\u201385.","journal-title":"Adv Pharmacol"},{"key":"3439_CR9","doi-asserted-by":"publisher","first-page":"116778","DOI":"10.1016\/j.jns.2020.116778","volume":"412","author":"MC Kalmoe","year":"2020","unstructured":"Kalmoe MC, Janski AM, Zorumski CF, Nagele P, Palanca BJ, Conway CR. Ketamine and nitrous oxide: the evolution of NMDA receptor antagonists as antidepressant agents. J Neurol Sci. 2020;412:116778. https:\/\/doi.org\/10.1016\/j.jns.2020.116778.","journal-title":"J Neurol Sci"},{"key":"3439_CR10","doi-asserted-by":"publisher","first-page":"176032","DOI":"10.1016\/j.ejphar.2023.176032","volume":"957","author":"G Wu","year":"2023","unstructured":"Wu G, Xu H. A synopsis of multitarget therapeutic effects of anesthetics on depression. Eur J Pharmacol. 2023;957:176032.","journal-title":"Eur J Pharmacol"},{"key":"3439_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-neuro-112723-062031","volume":"48","author":"M Smith Breault","year":"2025","unstructured":"Smith Breault M, Orguc S, Kwon O, Kang GH, Tseng B, Schreier DR, et al. Anesthetics as treatments for depression: clinical insights and underlying mechanisms. Annu Rev Neurosci. 2025;48:103\u201324.","journal-title":"Annu Rev Neurosci"},{"key":"3439_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.mehy.2009.11.021","volume":"74","author":"B Milne","year":"2010","unstructured":"Milne B. Nitrous oxide (laughing gas) inhalation as an alternative to electroconvulsive therapy. Med Hypotheses. 2010;74:780\u20131.","journal-title":"Med Hypotheses"},{"key":"3439_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/1874473711666181008163107","volume":"11","author":"MA Gillman","year":"2019","unstructured":"Gillman MA. Mini review: A brief history of nitrous oxide (N2O) use in neuropsychiatry. Curr Drug Res Rev. 2019;11:12\u201320.","journal-title":"Curr Drug Res Rev"},{"key":"3439_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fpsyt.2015.00172","volume":"6","author":"CF Zorumski","year":"2015","unstructured":"Zorumski CF, Nagele P, Mennerick S, Conway CR. Treatment-resistant major depression: rationale for NMDA receptors as targets and nitrous oxide as therapy. Front Psychiatry. 2015;6:172. https:\/\/doi.org\/10.3389\/fpsyt.2015.00172.","journal-title":"Front Psychiatry"},{"key":"3439_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nm0498-460","volume":"4","author":"V Jevtovic-Todorovic","year":"1998","unstructured":"Jevtovic-Todorovic V, Todorovic SM, Mennerick S, Powell S, Dikranian K, Benshoff N, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nature Medicine. 1998;4:460\u20133.","journal-title":"Nature Medicine"},{"key":"3439_CR16","doi-asserted-by":"publisher","first-page":"9716","DOI":"10.1523\/JNEUROSCI.18-23-09716.1998","volume":"18","author":"S Mennerick","year":"1998","unstructured":"Mennerick S, Jevtovic-Todorovic V, Todorovic SM, Shen W, Olney JW, Zorumski CF. Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures. J Neurosci. 1998;18:9716\u201326.","journal-title":"J Neurosci"},{"key":"3439_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/JCP.0000000000000837","volume":"38","author":"P Nagele","year":"2018","unstructured":"Nagele P, Zorumski CF, Conway C. Exploring nitrous oxide as treatment of mood disorders. Basic concepts. J Clin Psychopharmacol. 2018;38:144\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"3439_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/00002018-200629070-00008","volume":"29","author":"P Onody","year":"2006","unstructured":"Onody P, Gil P, Hennequin M. Safety of inhalation of a 50% nitrous oxide\/oxygen premix. A prospective survey of 35,828 administrations. Drug Safety. 2006;29:633\u201340.","journal-title":"Drug Safety"},{"key":"3439_CR19","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s00213-023-06449-w","volume":"240","author":"Y Qui","year":"2023","unstructured":"Qui Y, Li L, Duan A, Wang M, Xie M, Chen Z, et al. The efficacy and tolerability of inhaled nitrous oxide in major depressive disorder: a systematic review and meta-analysis. Psychopharmacol (Berl). 2023;240:2033\u201343.","journal-title":"Psychopharmacol (Berl)"},{"key":"3439_CR20","doi-asserted-by":"publisher","first-page":"e204693","DOI":"10.1001\/jamanetworkopen.2020.4693","volume":"3","author":"K Beck","year":"2020","unstructured":"Beck K, Hindley G, Borgan F, Ginestet C, McCutcheon R, Brugger S, et al. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia. JAMA Network Open. 2020;3:e204693.","journal-title":"JAMA Network Open"},{"key":"3439_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.clineuro.2013.04.004","volume":"115","author":"C Cousaert","year":"2013","unstructured":"Cousaert C, Heylens G, Audenaert K. Laughing gas abuse is no joke. An overview of the implications for psychiatric practice. Clin Neurol Neurosurg. 2013;115:859\u201362.","journal-title":"Clin Neurol Neurosurg"},{"key":"3439_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/add.16380","volume":"119","author":"S Back","year":"2024","unstructured":"Back S, Kroon E, Colyer-Patel K, Cousijn J. Does nitrous oxide addiction exist? An evaluation of the evidence for the presence and prevalence of substance use disorder symptoms in recreational nitrous oxide users. Addiction. 2024;119:609\u201318.","journal-title":"Addiction."},{"key":"3439_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1021\/acschemneuro.1c00761","volume":"13","author":"JN Highland","year":"2022","unstructured":"Highland JN, Morris PJ, Konrath KM, Riggs LM, Hagen NR, Zanos P, et al. Hydroxynorketamine pharmacokinetics and antidepressant behavioral effects of (2,6)- and (5R)-methyl-(2R,6R)-hydroxynorketamines. ACS Chem Neurosci. 2022;13:510\u201323.","journal-title":"ACS Chem Neurosci"},{"key":"3439_CR24","doi-asserted-by":"publisher","first-page":"e2305772120","DOI":"10.1073\/pnas.2305772120","volume":"49","author":"JH Krystal","year":"2023","unstructured":"Krystal JH, Kaye AP, Jefferson S, Girgenti MJ, Wilkinson ST, Sanacora G, et al. Ketamine and the neurobiology of depression: toward next-generation rapid-acting antidepressant treatments. Proc Natl Acad Sci. 2023;49:e2305772120.","journal-title":"Proc Natl Acad Sci"},{"key":"3439_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481\u20136.","journal-title":"Nature."},{"key":"3439_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.biopsych.2014.11.016","volume":"78","author":"P Nagele","year":"2015","unstructured":"Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M, et al. Nitrous oxide for treatment-resistant depression: a proof-of-concept trial. Biol Psychiatry. 2015;78:10\u2013182015.","journal-title":"Biol Psychiatry"},{"key":"3439_CR27","doi-asserted-by":"publisher","first-page":"eabe1376","DOI":"10.1126\/scitranslmed.abe1376","volume":"13","author":"P Nagele","year":"2021","unstructured":"Nagele P, Palanca BJ, Gott B, Brown F, Barnes L, Nguyen T, et al. A phase 2 trial of nitrous oxide for treatment-resistant major depression. Science Transl Med. 2021;13:eabe1376.","journal-title":"Science Transl Med."},{"key":"3439_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/acps.13432","volume":"146","author":"H Liu","year":"2022","unstructured":"Liu H, Kerzner J, Demchenko I, Wijeysundera DN, Kennedy SH, Ladha KS, et al. Nitrous oxide for the treatment of psychiatric disorders: a systematic review of the clinical trial landscape. Acta Psychiatr Scand. 2022;146:126\u201338.","journal-title":"Acta Psychiatr Scand"},{"key":"3439_CR29","doi-asserted-by":"publisher","first-page":"114867","DOI":"10.1016\/j.psychres.2022.114867","volume":"317","author":"D Yan","year":"2022","unstructured":"Yan D, Liu B, Wei X, Ou W, Liao M, Ji S, et al. Efficacy and safety of nitrous oxide for patients with treatment-resistant depression, a randomized controlled trial. Psychiatry Res. 2022;317:114867.","journal-title":"Psychiatry Res"},{"key":"3439_CR30","doi-asserted-by":"publisher","first-page":"115326","DOI":"10.1016\/j.psychres.2023.115326","volume":"326","author":"J Liu","year":"2023","unstructured":"Liu J, Zhao X, Wei X, Yan D, Ou W, Liao M, et al. Empirical evidence for the neurocognitive effect of nitrous oxide as an adjunctive therapy in patients with treatment resistant depression: a randomized controlled study. Psychiatry Res. 2023;326:115326.","journal-title":"Psychiatry Res"},{"key":"3439_CR31","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1038\/s41380-023-02217-6","volume":"28","author":"T Desmidt","year":"2023","unstructured":"Desmidt T, Dujardin P-A, Andersson F, Brizard B, Remenieras J-P, Gissot V, et al. Changes in cerebral connectivity and brain tissue pulsations with the antidepressant response to an equimolar mixture of oxygen and nitrous oxide: an MRI and ultrasound study. Mol Psychiatry. 2023;28:3900\u20138.","journal-title":"Mol Psychiatry"},{"key":"3439_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/bdi.13288","volume":"25","author":"WSH Kim","year":"2023","unstructured":"Kim WSH, Dimick MK, Omrin D, Mitchell RHB, Riegert D, Levitt A, et al. Proof-of-concept randomized controlled trial of single-session nitrous oxide for refractory bipolar depression: focus on cerebrovascular target engagement. Bipolar Disord. 2023;25:221\u201332.","journal-title":"Bipolar Disord"},{"key":"3439_CR33","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1192\/bjo.2025.10823","volume":"11","author":"KS Ladha","year":"2025","unstructured":"Ladha KS, Lee J, Mattina GF, Pazmino-Canizares J, Wijeysundera DN, Nezhad FG, et al. Sustained mood improvement with laughing gas exposure (SMILE): a randomized, placebo-controlled pilot trial of nitrous oxide for treatment-resistant depression. BJ Psych Open. 2025;11:e208. https:\/\/doi.org\/10.1192\/bjo.2025.10823. 1-7, 2025.","journal-title":"BJ Psych Open"},{"key":"3439_CR34","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1590\/1516-4445-2020-1543","volume":"43","author":"MC Guimaraes","year":"2021","unstructured":"Guimaraes MC, Guimaraes TM, Hallak JE, Abrao J, Machado-de-Sousa JP. Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial. Braz J Psychiatry. 2021;43:484\u201393. https:\/\/doi.org\/10.1590\/1516-4445-2020-1543.","journal-title":"Braz J Psychiatry"},{"key":"3439_CR35","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s42003-023-05678-1","volume":"6","author":"R Dai","year":"2023","unstructured":"Dai R, Huang Z, Larkin TE, Tarnal V, Picton P, Vlisides PE, et al. Psychedelic concentrations of nitrous oxide reduce functional differentiation in frontoparietal and somatomotor cortical networks. Commun Biol. 2023;6:1284. https:\/\/doi.org\/10.1038\/s42003-023-05678-1.","journal-title":"Commun Biol"},{"key":"3439_CR36","doi-asserted-by":"publisher","first-page":"120097","DOI":"10.1016\/j.neuroimage.2023.120097","volume":"273","author":"R Dai","year":"2023","unstructured":"Dai R, Larkin TE, Huang Z, Tarnal V, Picton P, Vlisides PE, et al. Classical and non-classical psychedelic drugs induce common network changes in human cortex. Neuroimage. 2023;273:120097.","journal-title":"Neuroimage."},{"key":"3439_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.biopsych.2019.10.026","volume":"88","author":"C Gratton","year":"2020","unstructured":"Gratton C, Kraus BT, Greene DJ, Gordon EM, Laumann TO, Nelson SM, et al. Defining individual-specific functional neuroanatomy for precision psychiatry. Biol Psychiatry. 2020;88:28\u201339.","journal-title":"Biol Psychiatry"},{"key":"3439_CR38","first-page":"698","volume":"3","author":"BJA Palanca","year":"2023","unstructured":"Palanca BJA, Conway CR, Zeffiro T, Gott BM, Nguyen T, Janski A, et al. Persistent brain connectivity changes in healthy volunteers following nitrous oxide inhalation. Biol Psychiatry Global Open. Science. 2023;3:698\u2013704.","journal-title":"Science."},{"key":"3439_CR39","doi-asserted-by":"publisher","unstructured":"Conway CR, Palanca BJA, Zeffiro T, Bott BM, Brown F, de Leon V, et al. Nitrous oxide alters functional connectivity in medial limbic structures in treatment-resistant major depression. MedRxiv. [Preprint]. 2024. https:\/\/doi.org\/10.1101\/2024.08.12.24311729. https:\/\/medrxiv.org\/cgi\/content\/short\/2024.08.12.24311729v1.","DOI":"10.1101\/2024.08.12.24311729"},{"key":"3439_CR40","doi-asserted-by":"publisher","first-page":"11020","DOI":"10.1073\/pnas.1000446107","volume":"107","author":"YI Sheline","year":"2010","unstructured":"Sheline YI, Price JL, Yan Z, Mintun MA. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci. 2010;107:11020\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"3439_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02674-1","volume":"13","author":"L Alexander","year":"2023","unstructured":"Alexander L, Hawkins PCT, Evans JW, Mehta MA, Zarate CA Jr. Preliminary evidence that ketamine alters anterior cingulate resting-state functional connectivity in depressed individuals. Transl Psychiatry. 2023;13:371. https:\/\/doi.org\/10.1038\/s41398-023-02674-1.","journal-title":"Transl Psychiatry"},{"key":"3439_CR42","doi-asserted-by":"publisher","first-page":"115072","DOI":"10.1016\/j.psychres.2023.115072","volume":"322","author":"X Shao","year":"2023","unstructured":"Shao X, Yan D, Kong W, Sun S, Liao M, Ou W, et al. Brain function changes reveal rapid antidepressant effects of nitrous oxide for treatment-resistant depression: evidence from task-state EEG. Psychiatry Res. 2023;322:115072.","journal-title":"Psychiatry Res"},{"key":"3439_CR43","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00406-022-01502-9","volume":"273","author":"G Kronenberg","year":"2023","unstructured":"Kronenberg G, Muller A, Seifritz E, Olbrich S. A distinct pattern of EEG and ECG changes associated with inhalational nitrous oxide\u2019s rapid antidepressant effects. Eur Arch Psych Clin Neurosci. 2023;273:1395\u20137. https:\/\/doi.org\/10.1007\/s00406-022-01502-9.","journal-title":"Eur Arch Psych Clin Neurosci"},{"key":"3439_CR44","first-page":"2058","volume":"45","author":"A Scalabrini","year":"2020","unstructured":"Scalabrini A, Vai B, Poletti S, Damiani S, Mucci C, Colombo C, et al. All roads lead to the default-mode network \u2013 global source of DMN abnormalities in major depressive disorder. Neuropharmacol. 2020;45:2058\u201369.","journal-title":"Neuropharmacol"},{"key":"3439_CR45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamapsychiatry.2015.0071","volume":"72","author":"RH Kaiser","year":"2015","unstructured":"Kaiser RH, Andrews-Hanna JR, Wager TD, PIzzagalli DA. Large scale network dysfunction in major depressive disorder: a meta-analysis of resting state functional connectivity. JAMA Psychiatry. 2015;72:603\u201311.","journal-title":"JAMA Psychiatry"},{"key":"3439_CR46","doi-asserted-by":"publisher","first-page":"8791","DOI":"10.1073\/pnas.0402825101","volume":"101","author":"P Nagele","year":"2004","unstructured":"Nagele P, Metz LB, Crowder CM. Nitrous oxide (N2O) requires the N-methyl-D-aspartate receptor for its action in Caenorhabditis elegans. Proc Natl Acad Sci. 2004;101:8791\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"3439_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF02245699","volume":"113","author":"DA Czech","year":"1993","unstructured":"Czech DA, Quock RM. Nitrous oxide induces an anxiolytic-like effect in the conditioned defensive burying paradigm, which can be reversed with a benzodiazepine receptor blocker. Psychopharmacol. 1993;113:211\u20136.","journal-title":"Psychopharmacol"},{"key":"3439_CR48","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00000542-200010000-00034","volume":"93","author":"Y Yamakura","year":"2000","unstructured":"Yamakura Y, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology. 2000;93:1095\u2013101.","journal-title":"Anesthesiology."},{"key":"3439_CR49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0026-895X(24)12624-7","volume":"60","author":"SM Todorovic","year":"2001","unstructured":"Todorovic SM, Jevtovic-Todorovic V, Mennerick S, Perez-Reyes E, Zorumski CF. Ca(v)3.2 channel is a molecular substrate for inhibition of T-type calcium currents in rat sensory neurons by nitrous oxide. Mol Pharmacol. 2001;60:603\u201310.","journal-title":"Mol Pharmacol"},{"key":"3439_CR50","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature25509","volume":"554","author":"Y Yang","year":"2018","unstructured":"Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554:317\u201322.","journal-title":"Nature."},{"key":"3439_CR51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.tins.2018.12.002","volume":"42","author":"Y Cui","year":"2019","unstructured":"Cui Y, Hu S, Hu H. Lateral habenula burst firing as a target of the rapid antidepressant effects of ketamine. Trends Neurosci. 2019;42:179\u201391.","journal-title":"Trends Neurosci"},{"key":"3439_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fnsyn.2018.00046","volume":"10","author":"CA Browne","year":"2018","unstructured":"Browne CA, Hammack R, Lucki I. Dysregulation of the lateral habenula in major depressive disorder. Front Synaptic Neurosci. 2018;10:46. https:\/\/doi.org\/10.3389\/fnsyn.2018.00046.","journal-title":"Front Synaptic Neurosci"},{"key":"3439_CR53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.conb.2017.10.024","volume":"48","author":"Y Yang","year":"2018","unstructured":"Yang Y, Wang H, Hu J, Hailan H. Lateral habenula in the pathophysiology of depression. Curr Op Neurobiol. 2018;48:90\u201396.","journal-title":"Curr Op Neurobiol"},{"key":"3439_CR54","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fpsyt.2019.00320","volume":"10","author":"PW Gold","year":"2019","unstructured":"Gold PW, Kadriu B. A major role for the lateral habenula in depressive illness: physiological and molecular mechanisms. Front Psychiatry. 2019;10:320. https:\/\/doi.org\/10.3389\/fpsyt.2019.00320.","journal-title":"Front Psychiatry"},{"key":"3439_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jad.2023.10.136","volume":"345","author":"C Chen","year":"2024","unstructured":"Chen C, Wang W, Yu T, Feng W, Xu Y, Ning Y, et al. Habenular functional connections are associated with depression state and modulated by ketamine. J Affective Dis. 2024;345:177\u201385.","journal-title":"J Affective Dis"},{"key":"3439_CR56","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1038\/s41380-025-03105-x","volume":"30","author":"J-S Fortin","year":"2025","unstructured":"Fortin J-S, Lafleur M, Parisien C, Hetu S. The habenula in mood disorders: a systematic review of human studies. Mol Psychiatry. 2025;30:4948\u201370.","journal-title":"Mol Psychiatry"},{"key":"3439_CR57","doi-asserted-by":"publisher","first-page":"9242","DOI":"10.1523\/JNEUROSCI.20-24-09242.2000","volume":"20","author":"S Sawamura","year":"2000","unstructured":"Sawamura S, Kingery WS, Davies MF, Agashe GS, Clark JD, Kobilka BK, et al. Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of 2B adrenoceptors. J Neurosci. 2000;20:9242\u201351.","journal-title":"J Neurosci"},{"key":"3439_CR58","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1097\/00000542-200212000-00018","volume":"97","author":"R Orii","year":"2002","unstructured":"Orii R, Ohashi Y, Gui T, Nelson LE, Hashimoto T, Maze M, et al. Evidence for the involvement of spinal cord alpha 1 adrenoceptors in nitrous oxide-induced antinociceptive effects in Fischer rats. Anethesiology. 2002;97:1458\u201365.","journal-title":"Anethesiology"},{"key":"3439_CR59","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1124\/mol.65.2.443","volume":"65","author":"M Gruss","year":"2004","unstructured":"Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, Franks NP. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol. 2004;65:443\u201352.","journal-title":"Mol Pharmacol"},{"key":"3439_CR60","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/ijnp\/pyab045","volume":"24","author":"MA Gilman","year":"2021","unstructured":"Gilman MA. Opioid properties of nitrous oxide and ketamine contribute to their antidepressant actions. Int J Neuropsychopharmacol. 2021;24:892\u20133.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3439_CR61","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/bja\/aeu254","volume":"113","author":"H Fukagawa","year":"2014","unstructured":"Fukagawa H, Koyama T, Kududa K. \u03ba-Opioid receptor mediates the antinociceptive effect of nitrous oxide in mice. Br J Anaesth. 2014;113:1032\u20138.","journal-title":"Br J Anaesth"},{"key":"3439_CR62","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/1043-6618(90)90733-T","volume":"22","author":"RM Quock","year":"1990","unstructured":"Quock RM, Walczak CK, Henry RJ, Chen DC. Effect of subtype-selective opioid receptor blockers on nitrous oxide antinociception in rats. Pharmacol Res. 1990;22:351\u20137.","journal-title":"Pharmacol Res"},{"key":"3439_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0014-2999(83)90626-X","volume":"89","author":"C Daras","year":"1983","unstructured":"Daras C, Cantrill RC, Gillman MA. 3[H]-Naloxone displacement: evidence for nitrous oxide as an opioid agonist. Eur J Pharmacol. 1983;89:177\u20138.","journal-title":"Eur J Pharmacol"},{"key":"3439_CR64","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/00000542-198903000-00027","volume":"70","author":"C Ori","year":"1989","unstructured":"Ori C, Ford-Rice F, London ED. Effects of nitrous oxide and halothane on mu and kappa opioid receptors in guinea pig brain. Anesthesiology. 1989;70:541\u20134.","journal-title":"Anesthesiology."},{"key":"3439_CR65","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-2999(97)01219-3","volume":"336","author":"F Fang","year":"1997","unstructured":"Fang F, Guo TZ, Davies MF, Maze M. Opiate receptor in the periaqueductal gray mediate analgesic effects of nitrous oxide in rats. Eur J Pharmacol. 1997;336:137\u201341.","journal-title":"Eur J Pharmacol"},{"key":"3439_CR66","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/00000542-200310000-00030","volume":"99","author":"Y Ohashi","year":"2003","unstructured":"Ohashi Y, Guo TY, Orii R, Maze M, Fujinaga M. Brain stem opioidergic and GABAergic neurons mediate the antinociceptive effect of nitrous oxide in Fischer rats. Anesthesiology. 2003;99:947\u201354.","journal-title":"Anesthesiology."},{"key":"3439_CR67","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1155\/2015\/809059","volume":"20","author":"M Ben Boujema","year":"2015","unstructured":"Ben Boujema M, Labouryras E, Pype J, Bessiere B, Simonnet G. Nitrous oxide persistently alleviates pain hypersensitivity in neuropathic rats: a dose-dependent effect. Pain Res Manag. 2015;20:309\u201315.","journal-title":"Pain Res Manag"},{"key":"3439_CR68","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1038\/s41591-025-03800-w","volume":"31","author":"LA Jelen","year":"2025","unstructured":"Jelen LA, Lythgoe DJ, Stone JM, Young AH, Mehta MA. Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study. Nature Medicine. 2025;31:2958\u201366.","journal-title":"Nature Medicine"},{"key":"3439_CR69","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1073\/pnas.1916570117","volume":"117","author":"ME Klein","year":"2020","unstructured":"Klein ME, Chandra J, Sheriff S, Malinow R. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci. 2020;117:2656\u201362.","journal-title":"Proc Natl Acad Sci"},{"key":"3439_CR70","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1176\/appi.ajp.20240378","volume":"182","author":"MR Levinstein","year":"2025","unstructured":"Levinstein MR, Budinich RC, Bonaventura J, Schatzberg AF, Zarate CA Jr, Michaelides M. Redefining ketamine pharmacology for antidepressant action: synergistic NMDA and opioid receptor interactions? Am J Psychiatry. 2025;182:247\u201358.","journal-title":"Am J Psychiatry"},{"key":"3439_CR71","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959\u201364.","journal-title":"Science."},{"key":"3439_CR72","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P-F, et al. NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature. 2011;475:91\u201395.","journal-title":"Nature."},{"key":"3439_CR73","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.neuron.2025.02.021","volume":"113","author":"F Lucantonio","year":"2025","unstructured":"Lucantonio F, Roeglin J, Li S, Lu J, Shi A, Czerpaniak K, et al. Ketamine rescues anhedonia by cell-type and input specific adaptations in the nucleus accumbens. Neuron. 2025;113:1398\u2013412.","journal-title":"Neuron."},{"key":"3439_CR74","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.biopsych.2021.05.008","volume":"90","author":"E Castren","year":"2021","unstructured":"Castren E, Monteggia LM. Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biol Psychiatry. 2021;90:128\u201336.","journal-title":"Biol Psychiatry"},{"key":"3439_CR75","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2021.12.003","volume":"185","author":"CS Wang","year":"2022","unstructured":"Wang CS, Kavalali ET, Monteggia LM. BDNF signaling in context: from synaptic regulation to psychiatric disorders. Cell. 2022;185:62\u201376.","journal-title":"Cell."},{"key":"3439_CR76","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.biopsych.2015.04.007","volume":"78","author":"CA Zarate Jr","year":"2015","unstructured":"Zarate CA Jr, Machado-Vieira R. Potential pathways involved in the rapid antidepressant effects of nitrous oxide. Biol Psychiatry. 2015;78:2\u20134.","journal-title":"Biol Psychiatry"},{"key":"3439_CR77","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.neuropharm.2014.08.002","volume":"86","author":"Y Izumi","year":"2014","unstructured":"Izumi Y, Zorumski CF. Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function. Neuropharmacol. 2014;86:273\u201381.","journal-title":"Neuropharmacol"},{"key":"3439_CR78","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.biopsych.2022.06.016","volume":"92","author":"Y Izumi","year":"2022","unstructured":"Izumi Y, Hsu F-F, Conway CR, Nagele P, Mennerick SJ, Zorumski CF. Nitrous oxide, a rapid antidepressant, has ketamine-like effects on excitatory transmission in adult hippocampus. Biological Psychiatry. 2022;92:964\u201372.","journal-title":"Biological Psychiatry"},{"key":"3439_CR79","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/0269881120985147","volume":"35","author":"L Bevilacqua","year":"2021","unstructured":"Bevilacqua L, Charney A, Pierce CR, Richards SM, Jha MK, Glasgow A, et al. Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial. J Psychopharmacol. 2021;35:124\u20137.","journal-title":"J Psychopharmacol"},{"key":"3439_CR80","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1124\/jpet.122.001346","volume":"384","author":"N Kotani","year":"2023","unstructured":"Kotani N, Jang I-S, Nakamura M, Nonaka K, Nagami H, Akaike N. Depression of synaptic NMDA responses by xenon and nitrous oxide. J Pharmacol Exp Therap. 2023;384:187\u201396.","journal-title":"J Pharmacol Exp Therap"},{"key":"3439_CR81","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.neuropharm.2006.09.021","volume":"52","author":"A Ranft","year":"2007","unstructured":"Ranft A, Kurz J, Becker K, Dodt HU, Zieglgansberger W, Rammes G, et al. Nitrous oxide (N2O) pre- and postsynaptically attenuates NMDA receptor-mediated neurotransmission in the amygdala. Neuropharmacology. 2007;52:716\u201323.","journal-title":"Neuropharmacology."},{"key":"3439_CR82","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1523\/JNEUROSCI.1316-22.2022","volume":"43","author":"P Zanos","year":"2023","unstructured":"Zanos P, Brown KA, Georgiou P, Yuan P, Zarate CA Jr, Thompson SM, et al. NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine. J Neurosci. 2023;43:1038\u201350.","journal-title":"J Neurosci"},{"key":"3439_CR83","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/bcpt.13598","volume":"129","author":"S Kohtala","year":"2021","unstructured":"Kohtala S, Rantamaki T. Rapid-acting antidepressants and the regulation of TrkB neurotrophic signaling \u2013 insights from ketamine, nitrous oxide, seizures and anaesthesia. Basic Clin Pharmacol Toxicol. 2021;129:95\u2013103.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3439_CR84","doi-asserted-by":"publisher","first-page":"11151","DOI":"10.1523\/JNEUROSCI.1203-16.2016","volume":"36","author":"E Khlestova","year":"2016","unstructured":"Khlestova E, Johnson JW, Krystal JH, Lisman J. The role of GluN2C-containing NMDA receptors in ketamine\u2019s psychotogenic action and in schizophrenia models. J Neurosci. 2016;36:11151\u20137.","journal-title":"J Neurosci"},{"key":"3439_CR85","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41386-023-01614-3","volume":"49","author":"JE Hanson","year":"2024","unstructured":"Hanson JE, Yuan H, Perszyk RE, Banke TG, Xing H, Tsai M-C, et al. Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Neuropsychopharmacol. 2024;49:51\u201366.","journal-title":"Neuropsychopharmacol"},{"key":"3439_CR86","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","volume":"36","author":"CF Zorumski","year":"2016","unstructured":"Zorumski CF, Izumi Y, Mennerick S. Ketamine: NMDA receptors and beyond. J Neurosci. 2016;36:11158\u201366.","journal-title":"J Neurosci"},{"key":"3439_CR87","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41386-023-01629-w","volume":"49","author":"JH Krystal","year":"2024","unstructured":"Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacol. 2024;49:41\u201350.","journal-title":"Neuropsychopharmacol"},{"key":"3439_CR88","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/00000542-200501000-00034","volume":"102","author":"K Nagashima","year":"2005","unstructured":"Nagashima K, Zorumski CF, Izumi Y. Nitrous oxide (laughing gas) facilitates excitability in rat hippocampal slices through \u03b3-aminobutyric acid A receptor-mediated disinhibition. Anesthesiology. 2005;102:230\u20134.","journal-title":"Anesthesiology."},{"key":"3439_CR89","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1007\/s12035-018-1364-6","volume":"56","author":"S Kohtala","year":"2019","unstructured":"Kohtala S, Theilmann W, Rosenholm M, Peena L, Karabulut G, Uusitalo S. Cortical excitability and activation of TrkB signaling during rebound slow oscillations are critical for rapid antidepressant responses. Mol Neurobiol. 2019;56:4163\u201374.","journal-title":"Mol Neurobiol"},{"key":"3439_CR90","doi-asserted-by":"publisher","first-page":"110172","DOI":"10.1016\/j.neuropharm.2024.110172","volume":"261","author":"O Alitalo","year":"2024","unstructured":"Alitalo O, Kohtala S, Rosenholm M, Saarreharju R, Gonzalez-Hernandez G, Sarparanta M, et al. Nitrous oxide induces hypothermia and TrkB activation: maintenance of body temperature abolishes antidepressant-like effects in mice. Neuropharmacol. 2024;261:110172.","journal-title":"Neuropharmacol"},{"key":"3439_CR91","doi-asserted-by":"publisher","unstructured":"Kohtala S, Parekh PK, Baramaki I, Kohtala P, Ilkka L, Antila H, et al. Nitrous oxide modulates cortical activity, wake-sleep oscillations, and produces antidepressant-like effects in mice. BioRxiv. [Preprint] 2025. https:\/\/doi.org\/10.1101\/2025.02.13.638096.","DOI":"10.1101\/2025.02.13.638096"},{"key":"3439_CR92","doi-asserted-by":"publisher","unstructured":"Valtonen P, Rozov S, Annala I, Jarventausta K, Subramaniyam NP, Tenhunen M, et al. Rebound electroencephalographic responses to nitrous oxide exposure in men. J Neurophysiol. 2025. https:\/\/doi.org\/10.1152\/jn.00275.2024.","DOI":"10.1152\/jn.00275.2024"},{"key":"3439_CR93","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3389\/fpsyt.2020.00837","volume":"11","author":"W Liu","year":"2020","unstructured":"Liu W, Li Q, Ye B, Cao H, Shen F, Xu Z, et al. Repeated nitrous oxide exposure exerts antidepressant-like effects through neuronal nitric oxide synthase activation in the medial prefrontal cortex. Front Psychiatry. 2020;11:837. https:\/\/doi.org\/10.3389\/fpsyt.2020.00837.","journal-title":"Front Psychiatry"},{"key":"3439_CR94","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s00213-002-1363-0","volume":"166","author":"S Li","year":"2003","unstructured":"Li S, Ohgami Y, Dai Y, Quock RM. Antagonism of nitrous oxide-induced anxiolytic-like behavior in the mouse light\/dark exploration procedure by pharmacologic disruption of endogenous nitric oxide function. Psychopharmacol. 2003;166:366\u201372.","journal-title":"Psychopharmacol"},{"key":"3439_CR95","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","volume":"63","author":"S Maeng","year":"2008","unstructured":"Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349\u201352.","journal-title":"Biol Psychiatry"},{"key":"3439_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57951-y","volume":"16","author":"J Cichon","year":"2025","unstructured":"Cichon J, Joseph TT, Lu X, Wasilczuk AZ, Kelz MB, Mennerick SJ, et al. Nitrous oxide activates layer 5 prefrontal neurons via SK2 channel inhibition for antidepressant effect. Nat Commun. 2025;16:2999. https:\/\/doi.org\/10.1038\/s41467-025-57951-y.","journal-title":"Nat Commun."},{"key":"3439_CR97","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1152\/jn.00583.2003","volume":"91","author":"HJ Abel","year":"2004","unstructured":"Abel HJ, Lee JCF, Callaway JC, Foehring RC. Relationships between intracellular calcium and afterhyperpolarization in neocortical pyramidal neurons. J Neurophysiol. 2004;91:324\u201335.","journal-title":"J Neurophysiol"},{"key":"3439_CR98","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1523\/JNEUROSCI.0182-04.2004","volume":"24","author":"CT Bond","year":"2004","unstructured":"Bond CT, Herson PS, Strassmaier T, Hammond R, Stackman R, Maylie J, et al. Small conductance Ca2+ -activated K+ channel knock-out mice reveal the identity of calcium-dependent afterhyperpolarization currents. J Neurosci. 2004;24:5301\u20136.","journal-title":"J Neurosci"},{"key":"3439_CR99","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1152\/jn.00524.2014","volume":"113","author":"D Guan","year":"2015","unstructured":"Guan D, Armstrong WE, Foehring RC. Electrophysiological properties of genetically identified subtypes of layer 5 neocortical pyramidal neurons: Ca2+ dependence and differential modulation by norepinephrine. J Neurophysiol. 2015;113:2014\u201332.","journal-title":"J Neurophysiol"},{"key":"3439_CR100","doi-asserted-by":"publisher","first-page":"20230225","DOI":"10.1098\/rstb.2023.0225","volume":"379","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Dong Y, Hu H. The N-methyl-D-aspartate receptor hypothesis of ketamine\u2019s antidepressant action: evidence and controversies. Phil Trans R Soc B. 2024;379:20230225.","journal-title":"Phil Trans R Soc B."},{"key":"3439_CR101","doi-asserted-by":"publisher","first-page":"176426","DOI":"10.1016\/j.ejphar.2024.176426","volume":"968","author":"S Rozov","year":"2024","unstructured":"Rozov S, Saarreharju R, Khirug S, Storvik M, Rivera C, Rantamaki T. Effects of nitrous oxide and ketamine on electrophysiological and molecular responses in the prefrontal cortex of mice: a comparative study. Eur J Pharmacol. 2024;968:176426. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176426.","journal-title":"Eur J Pharmacol"},{"key":"3439_CR102","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1213\/ANE.0000000000005835","volume":"134","author":"MA Brito","year":"2022","unstructured":"Brito MA, Li D, Fields CW, Rybicki-Kler C, Dean JG, Liu T, et al. Cortical acetylcholine levels correlate with neurophysiological complexity during subanesthetic ketamine and nitrous oxide exposure in rats. Anesth Analg. 2022;134:1126\u201339.","journal-title":"Anesth Analg"},{"key":"3439_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03257-y","volume":"15","author":"W-Q Li","year":"2025","unstructured":"Li W-Q, Liu S-N, Yang S-C, Lin X, Zhang Z-J. Nitrous oxide exerts rewarding effect via regulating D1 receptor and BDNF pathway in ventral tegmental-nucleus accumbens dopamine circuit. Transl Psychiatry. 2025;15:34. https:\/\/doi.org\/10.1038\/s41398-025-03257-y.","journal-title":"Transl Psychiatry"},{"key":"3439_CR104","doi-asserted-by":"publisher","first-page":"773190","DOI":"10.3389\/fpsyt.2022.773190","volume":"13","author":"MA Gillman","year":"2022","unstructured":"Gillman MA. What is better for psychiatry: titrated or fixed concentrations of nitrous oxide? Front Psychiatry. 2022;13:773190. https:\/\/doi.org\/10.3389\/fpsyt.2022.773190.","journal-title":"Front Psychiatry"},{"key":"3439_CR105","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1176\/appi.ajp.20230681","volume":"182","author":"AS Wolfgang","year":"2025","unstructured":"Wolfgang AS, Fonzo GA, Gray JC, Krystal JH, Grzenda A, Widge AS, et al. MDMA and MDMA-assisted therapy. Am J Psychiatry. 2025;182:79\u2013103.","journal-title":"Am J Psychiatry"},{"key":"3439_CR106","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1176\/appi.ajp.20230682","volume":"182","author":"GA Fonzo","year":"2025","unstructured":"Fonzo GA, Wolfgang AS, Barksdale BR, Krystal JH, Carpenter LL, Kraguljac NV, et al. Psilocybin: from psychiatric pariah to perceived panacea. Am J Psychiatry. 2025;182:54\u201378.","journal-title":"Am J Psychiatry"},{"key":"3439_CR107","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1176\/appi.ajp.20221043","volume":"181","author":"GM Goodwin","year":"2024","unstructured":"Goodwin GM, Malievskaia E, Fonzo GA, Nemeroff CB. Must psilocybin always \u201cassist psychotherapy\u201d? Am J Psychiatry. 2024;181:20\u201325.","journal-title":"Am J Psychiatry"},{"key":"3439_CR108","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1126\/science.abb6748","volume":"388","author":"ZZ Ma","year":"2025","unstructured":"Ma ZZ, Guzikowski NJ, Kim J-W, Kavalali ET, Monteggia LM. Enhanced ERK activity extends ketamine\u2019s antidepressant effects by augmenting synaptic plasticity. Science. 2025;388:646\u201355.","journal-title":"Science."},{"key":"3439_CR109","doi-asserted-by":"publisher","first-page":"22br14725","DOI":"10.4088\/JCP.22br14725","volume":"84","author":"V De Leon","year":"2023","unstructured":"De Leon V, Kumar A, Nagele P, Palanca BJ, Gott B, Janski A, et al. Nitrous oxide reduced suicidal ideation in treatment-resistant major depression in exploratory analysis. J Clin Psychiatry. 2023;84:22br14725.","journal-title":"J Clin Psychiatry"},{"key":"3439_CR110","doi-asserted-by":"publisher","first-page":"20113383","DOI":"10.4088\/JCP.20l13393","volume":"81","author":"A Varias","year":"2020","unstructured":"Varias A, van Roessel P, Parsiani M, Filippou-Frye M, Neylan TC, Nagele P, et al. Does nitrous oxide help veterans with posttraumatic stress disorder? J Clin Psychiatry. 2020;81:20113383.","journal-title":"J Clin Psychiatry"},{"key":"3439_CR111","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1017\/S003329171600026X","volume":"46","author":"RK Das","year":"2016","unstructured":"Das RK, Tamman A, Nikolova V, Freeman TP, Bisby JA, Lazzarino AI, et al. Nitrous oxide speeds the reduction of distressing intrusive memories in an experimental model of psychological trauma. Psychol Med. 2016;46:1749\u201359.","journal-title":"Psychol Med"},{"key":"3439_CR112","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41386-024-02049-0","volume":"50","author":"E Williams","year":"2025","unstructured":"Williams E, Taujanskaite U, Kamboj SK, Murphy SE, Harmer CJ. Examining memory reconsolidation as a mechanism of nitrous oxide\u2019s antidepressant action. Neuropsychopharmacol. 2025;50:609\u201317.","journal-title":"Neuropsychopharmacol"},{"key":"3439_CR113","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.euroneuro.2018.05.001","volume":"28","author":"RK Das","year":"2018","unstructured":"Das RK, Walsh K, Hannaford J, Lazzarino AI, Kamboj SK. Nitrous oxide may interfere with the reconsolidation of drinking memories in hazardous drinkers in a prediction-error-dependent manner. Eur J Neuropsychopharmacol. 2018;28:828\u201340.","journal-title":"Eur J Neuropsychopharmacol"},{"key":"3439_CR114","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/0091-3057(94)90333-6","volume":"48","author":"PW Caton","year":"1994","unstructured":"Caton PW, Tousman SA, Quock RM. Involvement of nitric oxide in nitrous oxide anxiolysis in the elevated plus maze. Pharmacol Biochem Behav. 1994;48:689\u201392.","journal-title":"Pharmacol Biochem Behav"},{"key":"3439_CR115","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF02244768","volume":"115","author":"DE Emmanouil","year":"1994","unstructured":"Emmanouil DE, Johnson CH, Quock RM. Nitrous oxide anxiolytic effect in mice in the elevated plus maze: mediation by benzodiazepine receptors. Psychopharmacol. 1994;115:167\u201372.","journal-title":"Psychopharmacol"},{"key":"3439_CR116","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.pbb.2006.05.016","volume":"84","author":"DE Emmanouil","year":"2006","unstructured":"Emmanouil DE, Papadopoulou-Daifoti Z, Hagihara PT, Quock DG, Quock RM. A study of the role of serotonin in the anxiolytic effect of nitrous oxide in rodents. Pharmacol Biochem Behav. 2006;84:313\u201320.","journal-title":"Pharmacol Biochem Behav"},{"key":"3439_CR117","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ceca.2009.09.002","volume":"46","author":"P Bartels","year":"2009","unstructured":"Bartels P, Behnke K, Michels G, Groner F, Schneider T, Henry M, et al. Structural and biophysical determinants of single Ca(v)3.1 and Ca(v)3.2 T-type calcium channel inhibition by N(2)O. Cell Calcium. 2009;46:293\u2013302.","journal-title":"Cell Calcium"},{"key":"3439_CR118","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1113\/jphysiol.2010.196220","volume":"589","author":"P Orestes","year":"2011","unstructured":"Orestes P, Bojadzic D, Lee J, Leach E, Salajegheh R, Digruccio MR, et al. Free radical signaling underlies inhibition of Cav3.2 T-type calcium channels by nitrous oxide in the pain pathway. J Physiology. 2011;589:135\u201348.","journal-title":"J Physiology"},{"key":"3439_CR119","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/PL00000638","volume":"57","author":"Y-B Choi","year":"2000","unstructured":"Choi Y-B, Lipton SA. Redox modulation of the NMDA receptor. Cell Mol Life Sci. 2000;57:1535\u201341.","journal-title":"Cell Mol Life Sci"},{"key":"3439_CR120","doi-asserted-by":"publisher","first-page":"eado7010","DOI":"10.1126\/science.ado7010","volume":"385","author":"M Chen","year":"2024","unstructured":"Chen M, Ma S, Liu H, Dong Y, Tang J, Ni Z, et al. Brain region-specific action of ketamine as a rapid antidepressant. Science. 2024;385:eado7010.","journal-title":"Science."},{"key":"3439_CR121","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fncel2018.00135","volume":"12","author":"F Chamaa","year":"2018","unstructured":"Chamaa F, Bahmad HF, Makkawi A-K, Chalhoub RM, Al-Chaer ED, Bikhazi GB, et al. Nitrous oxide induces prominent cell proliferation in adult rat hippocampal dentate gyrus. Front Cell Neurosci. 2018;12:135. https:\/\/doi.org\/10.3389\/fncel2018.00135.","journal-title":"Front Cell Neurosci"},{"key":"3439_CR122","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/npp.2016.186","volume":"42","author":"CG Abdallah","year":"2017","unstructured":"Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, et al. Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacol. 2017;42:1210\u20139.","journal-title":"Neuropsychopharmacol"},{"key":"3439_CR123","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41380-022-01465-2","volume":"27","author":"DE Holmes","year":"2022","unstructured":"Holmes DE, Finnema S, Naganawa M, DellaGioia N, Holden D, Fowles K, et al. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Mol Psychiatry. 2022;27:2273\u201381.","journal-title":"Mol Psychiatry"},{"key":"3439_CR124","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pscychresns.2018.09.001","volume":"283","author":"AC Nugent","year":"2019","unstructured":"Nugent AC, Wills KE, Gilbert JR, Zarate CA Jr. Synaptic potentiation and rapid antidepressant responses to ketamine in treatment-resistant major depression: a replication study. Psychiatry Res Neuroimag. 2019;283:64\u201366.","journal-title":"Psychiatry Res Neuroimag"},{"key":"3439_CR125","doi-asserted-by":"publisher","first-page":"eaat88078","DOI":"10.1126\/science.aat8078","volume":"364","author":"RN Moda-Sava","year":"2019","unstructured":"Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364:eaat88078.","journal-title":"Science"},{"key":"3439_CR126","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41593-022-01203-5","volume":"26","author":"J Cichon","year":"2022","unstructured":"Cichon J, Wasilczuk AZ, Looger LL, Contreras D, Kelz MB, Proekt A. Ketamine triggers a switch in excitatory neuronal activity across neocortex. Nature Neurosci. 2022;26:39\u201352.","journal-title":"Nature Neurosci"},{"key":"3439_CR127","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamapsychiatry.2023.1576","volume":"80","author":"TO Laumann","year":"2023","unstructured":"Laumann TO, Zorumski CF, Dosenbach NUF. Precision neuroimaging for localization-related psychiatry. JAMA Psychiatry. 2023;80:763\u20134.","journal-title":"JAMA Psychiatry"},{"key":"3439_CR128","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cobeha.2021.03.017","volume":"40","author":"CJ Lynch","year":"2021","unstructured":"Lynch CJ, Elbau I, Liston C. Improving precision functional mapping routines with multi-echo fMRI. Curr Opin Behav Sci. 2021;40:113\u20139.","journal-title":"Curr Opin Behav Sci"},{"key":"3439_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0239-y","volume":"8","author":"PJ Fitzgerald","year":"2018","unstructured":"Fitzgerald PJ, Watson BO. Gamma oscillations as a biomarker for major depression: an emerging topic. Transl Psychiatry. 2018;8:177. https:\/\/doi.org\/10.1038\/s41398-018-0239-y.","journal-title":"Transl Psychiatry"},{"key":"3439_CR130","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41386-022-01450-x","volume":"48","author":"PM Lambert","year":"2023","unstructured":"Lambert PM, Ni R, Benz A, Rensing NR, Wong M, Zorumski CF, et al. Non-sedative cortical EEG signatures of allopregnanolone and functional comparators. Neuropsychopharmacol. 2023;48:371\u20139.","journal-title":"Neuropsychopharmacol"},{"key":"3439_CR131","doi-asserted-by":"publisher","first-page":"e1545242025","DOI":"10.1523\/JNEUROSCI.1545-24.2025","volume":"45","author":"DG Davilia","year":"2025","unstructured":"Davilia DG, McKinstry-Wu A, Kelz MB, Proekt A. The administration of ketamine is associated with dose-dependent stabilization of cortical dynamics in humans. J Neurosci. 2025;45:e1545242025.","journal-title":"J Neurosci"},{"key":"3439_CR132","first-page":"8","volume":"14","author":"MS Willsey","year":"2021","unstructured":"Willsey MS, Nu CS, Nason SR, Schroeder KE, Hutchison BC, Welle EJ, et al. Neural dynamics in primate cortex during exposure to subanesthetic concentrations of nitrous oxide. eNeuro. 2021;14:8. ENEURO.0479-20.2021","journal-title":"eNeuro"},{"key":"3439_CR133","doi-asserted-by":"publisher","unstructured":"Brenna CTA, Goldstein BI, Zarate Jr CA, Orser BA Repurposing general anesthetics drugs to treat depression: a new frontier for anesthesiologists in neuropsychiatric care. Anesthesiology. 2024. https:\/\/doi.org\/10.1097\/ALN.05037.","DOI":"10.1097\/ALN.05037"},{"key":"3439_CR134","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00540-023-03291-4","volume":"38","author":"H Tateiwa","year":"2024","unstructured":"Tateiwa H, Evers AS. Neurosteroids and their potential as a safer class of general anesthetics. J Anesthesia. 2024;38:261\u201374.","journal-title":"J Anesthesia"},{"key":"3439_CR135","doi-asserted-by":"publisher","first-page":"100196","DOI":"10.1016\/j.ynstr.2019.10096","volume":"11","author":"CF Zorumski","year":"2019","unstructured":"Zorumski CF, Paul SM, Covey DF, Mennerick S. Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond. Neurobiol Stress. 2019;11:100196. https:\/\/doi.org\/10.1016\/j.ynstr.2019.10096.","journal-title":"Neurobiol Stress"},{"key":"3439_CR136","doi-asserted-by":"publisher","unstructured":"Zorumski CF, Covey DF, Izumi Y, Evers AS, Maguire JL, Mennerick SJ New directions in neurosteroid therapeutics in neuropsychiatry. Neurosci Biobehav Rev. 2025. https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106119.","DOI":"10.1016\/j.neubiorev.2025.106119"},{"key":"3439_CR137","doi-asserted-by":"publisher","unstructured":"Nagele P, Conway C, Zorumski CF Purposeful drug repurposing. JAMA Psychiatry. 2025. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0900.","DOI":"10.1001\/jamapsychiatry.2025.0900"},{"key":"3439_CR138","doi-asserted-by":"publisher","first-page":"pyaf027","DOI":"10.1093\/ijnp\/pyaf027","volume":"28","author":"N Zaki","year":"2025","unstructured":"Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, et al. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. Int J Neuropsychopharmacol. 2025;28:pyaf027. https:\/\/doi.org\/10.1093\/ijnp\/pyaf027.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3439_CR139","doi-asserted-by":"publisher","unstructured":"Myles F, Kulkarni J, Kasza J, Wallace S, Deng C, Turbic A, et al. Antidepressant effects of nitrous oxide in major depressive disorder: a phase 2b randomized clinical trial. Biological Psychiatry Glb Op Sci. 2025. https:\/\/doi.org\/10.1016\/j.bpsgos.2025.100504.","DOI":"10.1016\/j.bpsgos.2025.100504"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03439-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:04:30Z","timestamp":1779282270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03439-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":139,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3439"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03439-6","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CFZ served on the Scientific Advisory Board of Sage Therapeutics and had equity in the company. Sage Therapeutics did not fund or participate in this work. PN is a co-founder of NitroTherapeutics, Inc., which aims to develop nitrous oxide as a treatment for mood disorders. Other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}